NCT02683863View on ClinicalTrials.gov

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

BG00012 (DMF) (Tecfidera®.)

Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.

Trial Locations (1)

12110

Multiple Sclerosis Center of Northeastern New York, Latham

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Multiple Sclerosis Center of Northeastern New York

OTHER